Loading candles…
Brooks Laboratories Ltd, incorporated in 2002, is an Indian pharmaceutical company engaged in contract manufacturing and trading. The company focuses on producing therapeutic formulations, particularly high-end injectable dosages, catering primarily to the critical care segment. It operates in both domestic and international pharmaceutical markets. Brooks Laboratories has a manufacturing facility located in Baddi, Himachal Pradesh, which is designed to comply with international regulatory standards such as GMP and GLP.
This page is a live market overview for BROOKS LAB LIMITED (BROOKS) on the NSE. As a listed security, BROOKS LAB LIMITED is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for BROOKS before placing trades on tick2trade.
As of the latest feed, BROOKS last traded at ₹60.6 on NSE, up ₹1.51 (2.56%) from the previous close of ₹59.09. Today's session range is ₹59.09 – ₹62.49, against a 52-week band of ₹36.3 – ₹156.99. Traded volume today stands at 78.61K shares.
The overview consolidates an interactive price chart with multiple time ranges, five-level bid and ask depth, recent market headlines, upcoming corporate events for BROOKS in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether BROOKS is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for BROOKS LAB LIMITED before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in BROOKS. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated BROOKS option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 13 Aug 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 | 29 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 6 Feb 2026 |
| Unaudited Results - FY25 | To consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended 30 September 2025 and Other business | 14 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 and other business. | 13 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 | 28 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.